Oncolytics Biotech is trading 5.32% up at $0.45, with no clear company-specific announcement identified on November 5 to explain the gain.
- Biotechnology ETF XBI was down 5.95% in Nasdaq’s November 5 update, while CNN reported a broad technology-led sell-off.
- Encouraging anal-cancer translational data were announced November 4, but a connection to today’s move is unconfirmed.